Extracellular matrix structures

Abstract

A sheet structure comprising two joined extracellular matrix (ECM) tissue or sheet layers and a physiological sensor disposed therebetween; the ECM tissue being derived from a mammalian tissue source that includes small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.

1 - 8 . (canceled) 
     
     
         9 . A tissue prosthesis comprising:
 an extracellular matrix (ECM) composition comprising ECM derived from a mammalian tissue source;   wherein the mammalian tissue source is selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), central nervous system tissue, mesothelial tissue, dermal tissue, gastrointestinal tissue, placental tissue, omentum tissue, cardiac tissue, kidney tissue, pancreas tissue, lung tissue, collagen, urinary basement membrane (UBM), liver basement membrane (LBM), amnion, chorion, allograft pericardium, allograft acellular dermis, amniotic membrane, Wharton's jelly, and combinations thereof; and   wherein the ECM comprises decellularized ECM.   
     
     
         10 . The tissue prosthesis of  claim 9 , wherein the ECM comprises acellular ECM. 
     
     
         11 . The tissue prosthesis of  claim 9 , wherein the mammalian tissue source is selected from the group consisting of placental tissue, amnion, chorion, amniotic membrane, Wharton's jelly, and combinations thereof. 
     
     
         12 . The tissue prosthesis of  claim 9 , wherein the mammalian tissue source is placental tissue. 
     
     
         13 . The tissue prosthesis of  claim 9 , wherein the ECM composition further comprises a biologically active agent. 
     
     
         14 . The tissue prosthesis of  claim 13 , wherein the biologically active agent comprises a growth factor selected from the group consisting of platelet derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor alpha (TGF-alpha), transforming growth factor beta (TGF-beta), fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF), vascular epithelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), nerve growth factor (NGF), platelet derived growth factor (PDGF), tumor necrosis factor alpha (TNA-alpha), placental growth factor (PLGF), and combinations thereof. 
     
     
         15 . The tissue prosthesis of  claim 13 , wherein the biologically active agent comprises a cell selected from the group consisting of human embryonic stem cells, fetal cardiomyocytes, myofibroblasts, mesenchymal stem cells, autotransplanted expanded cardiomyocytes, adipocytes, totipotent cells, pluripotent cells, blood stem cells, myoblasts, adult stem cells, bone marrow cells, mesenchymal cells, embryonic stem cells, parenchymal cells, epithelial cells, endothelial cells, mesothelial cells, fibroblasts, osteoblasts, chondrocytes, exogenous cells, endogenous cells, stem cells, hematopoietic stem cells, bone-marrow derived progenitor cells, myocardial cells, skeletal cells, fetal cells, undifferentiated cells, multi-potent progenitor cells, unipotent progenitor cells, monocytes, cardiac myoblasts, skeletal myoblasts, macrophages, capillary endothelial cells, xenogenic cells, allogenic cells, post-natal stem cells, and combinations thereof. 
     
     
         16 . The tissue prosthesis of  claim 13 , wherein the biologically active agent is selected from the group consisting of collagen (types I-V), proteoglycans, glycosaminoglycans (GAGs), glycoproteins, growth factors, cytokines, cell-surface associated proteins, cell adhesion molecules (CAM), angiogenic growth factors, endothelial ligands, matrikines, cadherins, immuoglobins, fibril collagens, non-fibrillar collagens, basement membrane collagens, multiplexins, small-leucine rich proteoglycans, decorins, biglycans, fibromodulins, keratocans, lumicans, epiphycans, heparan sulfate proteoglycans, perlecans, agrins, testicans, syndecans, glypicans, serglycins, selectins, lecticans, aggrecans, versicans, neurocans, brevicans, cytoplasmic domain-44 (CD-44), macrophage stimulating factors, amyloid precursor proteins, heparins, chondroitin sulfate B (dermatan sulfate), chondroitin sulfate A, heparan sulfates, hyaluronic acids, fibronectins, tenascins, elastins, fibrillins, laminins, nidogen/enactins, fibulin I, finulin II, integrins, transmembrane molecules, thrombospondins, ostepontins, angiotensin converting enzymes (ACE), and combinations thereof. 
     
     
         17 . The tissue prosthesis of  claim 9 , wherein the ECM composition further comprises a pharmacological agent. 
     
     
         18 . The tissue prosthesis of  claim 17 , wherein the pharmacological agent is selected from the group consisting of antibiotics, anti-arrhythmic agents, anti-viral agents, analgesics, anti-inflammatory agents, anti-neoplastics, anti-spasmodics, modulators of cell-extracellular matrix interactions, proteins, hormones, growth factors, matrix metalloproteinases (MMPS), enzymes, enzyme inhibitors, anticoagulants, antithrombic agents, DNA, RNA, modified DNA, modified RNA, NSAIDs, inhibitors of DNA synthesis, inhibitors of RNA synthesis, inhibitors of protein synthesis, polypeptides, oligonucleotides, polynucleotides, nucleoproteins, compounds modulating cell migration, compounds modulating tissue proliferation, compounds modulating tissue growth, vasodilating agents, and combinations thereof. 
     
     
         19 . The tissue prosthesis of  claim 17 , wherein the pharmacological agent comprises an anti-inflammatory agent. 
     
     
         20 . The tissue prosthesis of  claim 9 , wherein the tissue prosthesis comprises a sheet structure. 
     
     
         21 . A method of treating a damaged cardiovascular structure of a patient, the method comprising delivering the tissue prosthesis of  claim 9  to the damaged cardiovascular structure. 
     
     
         22 . The method of  claim 21 , wherein delivering the tissue prosthesis to the damaged cardiovascular tissue modulates inflammation in the damaged cardiovascular tissue. 
     
     
         23 . The method of  claim 21 , wherein delivering the tissue prosthesis to the damaged cardiovascular tissue modulates healing in the damaged cardiovascular tissue. 
     
     
         24 . The method of  claim 21 , wherein delivering the tissue prosthesis to the damaged cardiovascular tissue induces tissue proliferation, remodeling, and regeneration in the damaged cardiovascular tissue. 
     
     
         25 . The method of  claim 21 , wherein delivering the tissue prosthesis to the damaged cardiovascular tissue substantially reduces a risk of thrombosis for the patient. 
     
     
         26 . The method of  claim 21 , wherein delivering the tissue prosthesis to the damaged cardiovascular tissue substantially reduces a risk of intimal hyperplasia for the patient. 
     
     
         27 . The method of  claim 21 , wherein delivering the tissue prosthesis to the damaged cardiovascular tissue substantially reduces a risk of a harsh biological response associated with a conventional prosthesis for the patient. 
     
     
         28 . The method of  claim 21 , wherein delivering the tissue prosthesis to the damaged cardiovascular tissue substantially reduces a risk of biofilm formation, inflammation, and infection for the patient.